Paper Details

  1. Home
  2. Paper Details

Effects of raltegravir or elvitegravir resistance signature mutations on the barrier to dolutegravir resistance in vitro.

Author: AkihisaErika, FujiwaraTamio, Kawauchi-MikiShinobu, KobayashiMasanori, MikiShigeru, NakaharaKoichiro, SatoAkihiko, SekiTakahiro, Suyama-KagitaniAkemi, UnderwoodMark R, Wakasa-MorimotoChiaki, YoshinagaTomokazu

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study examined the resistance profile of dolutegravir (DTG), a new HIV-1 integrase strand transfer inhibitor (INSTI), against various HIV-1 mutations. DTG was found to have a high barrier to resistance in the presence of mutations associated with resistance to other INSTIs, such as raltegravir and elvitegravir.
Paper Details　
Original Abstract of the Article :
The recently approved HIV-1 integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) (S/GSK1349572) has overall advantageous activity when tested in vitro against HIV-1 with raltegravir (RAL) and elvitegravir (EVG) resistance signature mutations. We conducted an in vitro resistance selection s...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4394817/

データ提供：米国国立医学図書館（NLM）

Dolutegravir: A New Bastion Against HIV Resistance

HIV, a relentless desert storm that continues to threaten global health, requires constant vigilance and innovation. This research explores the effectiveness of a new antiretroviral drug, dolutegravir (DTG), in combating the emergence of resistance to other integrase strand transfer inhibitors (INSTIs), like raltegravir (RAL) and elvitegravir (EVG). The authors conducted in vitro resistance studies, finding that DTG demonstrated a high barrier to the development of resistance, even in the presence of mutations associated with RAL and EVG resistance. These findings suggest that DTG could be a valuable tool in managing HIV infection and preventing the emergence of drug resistance.

A New Fortress in the Fight Against HIV

This study offers a glimmer of hope in the ongoing battle against HIV. The research suggests that DTG, a new antiretroviral drug, offers a promising solution for combating drug resistance. This study underscores the importance of developing new medications that effectively target the virus and prevent the emergence of resistant strains. This research offers a potential pathway for improving HIV treatment outcomes and enhancing patient care.

Staying Safe in the Desert: Managing HIV Infection

Managing HIV infection requires a comprehensive approach, including adherence to medication regimens, regular monitoring, and a healthy lifestyle. This research highlights the importance of ongoing research and innovation in developing new and effective treatments for HIV infection.

Dr.Camel's Conclusion

This study, like a valiant knight defending a fortress against an unrelenting enemy, explores the effectiveness of a new antiretroviral drug, dolutegravir (DTG), in combating HIV resistance. The research suggests that DTG offers a promising solution for managing HIV infection and preventing the emergence of drug resistance. This study is a reminder that ongoing research and innovation are essential in the fight against this devastating disease.
Date :
  1. Date Completed 2016-01-11
  2. Date Revised 2021-08-26
Further Info :

Pubmed ID

25691633

DOI: Digital Object Identifier

PMC4394817

Related Literature

Article Analysis
・Effects of raltegravir・Effects of dolutegravir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.